Rising Cancer Burden Fueling The Growth Of The Market Due To Increasing Incidence Driven By Lifestyle Factors: Pivotal Factor Influencing Biomarker Testing Market Growth in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Biomarker Testing Market Size Growth Forecast: What to Expect by 2025?
In the past few years, the biomarker testing market size has experienced a swift expansion. Its growth is projected from $17.51 billion in 2024 to $19.75 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 12.8%. Such growth during the historical period can be linked to the rising adoption of personalized medicine, the growing employment of biomarkers in oncology, the escalating frequency of chronic diseases, the surge in research funding in the field of life sciences, and the mounting demand for early detection of diseases.

How Will the Biomarker Testing Market Size Evolve and Grow by 2029?
The size of the biomarker testing market is forecasted to experience a swift expansion in the coming years, reaching $31.63 billion in 2029 with a compound annual growth rate (CAGR) of 12.5%. The anticipated growth during the forecast period is largely due to the increasing use of biomarkers in non-oncology diseases, escalating investments in companion diagnostics, greater incorporation of artificial intelligence into diagnostics, the broadening application of point-of-care testing, and a growing consciousness about preventive healthcare. Key trends predicted for the forecast period are progress in sequencing technologies, consistent breakthroughs in liquid biopsy, advancements in multiplex biomarker platforms, novelties in proteomics and metabolomics, and funding towards research and development.

View the full report here:
https://www.thebusinessresearchcompany.com/report/biomarker-testing-global-market-report

What Drivers Are Propelling the Growth of Biomarker Testing Market Forward?
The escalating incidence of cancer is projected to drive the expansion of the biomarker testing market in the future. Cancer is essentially a collection of diseases that exhibit unregulated proliferation and diffusion of abnormal cells within the body. This growing prevalence of cancer is linked to lifestyle factors such as unhealthy eating habits, smoking, lack of physical exercise, and overconsumption of alcohol. Biomarker testing augments cancer detection by facilitating the timely and precise determination of disease-specific indicators, thereby enhancing diagnostic precision. It also aids in the formulation of personalized treatment strategies, resulting in superior patient results and more efficient healthcare administration. For example, The Australian Institute of Health and Welfare, a government agency based in Australia, revealed in July 2024 that cancer diagnoses in Australia had escalated to 160,570 in 2022, a surge of 3,789 cases as compared to 156,781 in 2021. Consequently, the increasing incidence of cancer is stimulating the expansion of the biomarker testing market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24480&type=smp

Which Emerging Trends Are Transforming the Biomarker Testing Market in 2025?
Leading firms in the biomarker testing market are concentrating on the creation of technologically sophisticated solutions, such as immunohistochemistry (IHC) technology to boost diagnostic precision, facilitate early detection of diseases, and endorse personalized treatment approaches. IHC technology is a lab process that employs antibodies to identify specific proteins in tissue specimens, assisting in the identification and visualization of biomarkers for disease diagnosis and research. For example, Quest Diagnostics Incorporated, a medical laboratories corporation based in the United States, launched a new tissue-based prostate cancer biomarker test through its AmeriPath division in July 2023. This test employs proprietary biomarkers EV1, EV2, and EV3 to improve diagnostic precision. It serves a crucial clinical need by aiding doctors in accurately identifying and distinguishing aggressive forms of prostate cancer, enhancing grading uniformity, and directing suitable treatment strategies for patients.

What Are the Key Segments in the Biomarker Testing Market?
The biomarker testing market covered in this report is segmented -

1) By Product Type: Consumables, Instruments, Services
2) By Technology: Polymerase Chain Reaction, Next-Generation Sequencing, Immunoassays, Other Technologies
3) By Application: Oncology, Cardiology, Neurology, Infectious Diseases, Other Applications
4) By End-User: Hospitals, Diagnostic Laboratories, Research Institutes, Other End-Users

Subsegments:
1) By Consumables: Reagents, Assay Kits, Sample Collection Devices, Chemicals And Buffers
2) By Instruments: Polymerase Chain Reaction (PCR) Systems, Next-Generation Sequencing (NGS) Platforms, Microarray Systems, Mass Spectrometry Instruments, Immunoassay Analyzers
3) By Services: Biomarker Discovery Services, Diagnostic Testing Services, Companion Diagnostic Development, Clinical Trial Testing Services, Contract Research Organization (CRO) Services

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24480&type=smp

Who Are the Key Players Shaping the Biomarker Testing Market's Competitive Landscape?
Major companies operating in the biomarker testing market are Roche Diagnostics International Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthineers AG, Becton Dickinson and Company, GE HealthCare Technologies Inc., Agilent Technologies Inc., Illumina Inc., Hologic Inc., Charles River Laboratories International Inc., PerkinElmer Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Myriad Genetics Inc., Guardant Health Inc., Sino Biological Inc., Proteome Sciences plc

What Geographic Markets Are Powering Growth in the Biomarker Testing Market?
North America was the largest region in the biomarker testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biomarker testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24480

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.